Hansen Medical's Magellan(TM) Robotic System to Be Presented at

Hansen Medical's Magellan(TM) Robotic System to Be Presented at 39th
Annual VEITHsymposium(TM) of Vascular Surgeons and Interventionalists 
MOUNTAIN VIEW, CA -- (Marketwire) -- 11/09/12 --  Hansen Medical,
Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today
announced it will exhibit its Magellan(TM) Robotic System at the 39th
Annual VEITHsymposium(TM) from November 13-17 at the Hilton New York
in New York City. The Company will be conducting product
demonstrations and exhibiting the Magellan Robotic System at Booth
Additionally, Hansen Medical will be co-sponsoring a symposium with
Philips at noon on Thursday, November 15th. The symposium, titled New
Frontiers in Hybrid OR, Advanced Imaging and Intravascular Robotics,
will feature Professor Nick Cheshire, M.D. from St. Mary's Hospital
in London and Dr. Jean Bismuth from Methodist Hospital in Houston,
who will share their clinical experiences with the Magellan Robotic
Hansen Medical also anticipates that the Magellan Robotic System will
be featured in the following scheduled presentations:  

--  3D Imaging and Robotic Catheter Navigation: How Can They Work Together
    to Facilitate Complex Aortic Procedures; by Alan B. Lumsden, M.D.,
    FACS; Friday, November 16, 2012, 7:59 a.m.
--  The Value of Hansen Magellan Robotic Assisted Catheter Manipulation
    for Complex Aortic Endografting, by Nicholas J.W. Cheshire, M.D.;
    Friday, November 16, 2012, 2:24 p.m.

"The VEITHsymposium is one of the year's seminal vascular conferences
and we are delighted to have our Magellan System featured in such a
prominent manner," said Bruce Barclay, President and CEO of Hansen
Medical. "Moreover, the timing of this meeting allows physicians to
discuss their early use of Magellan for a variety of intravascular
procedures, and continues the momentum generated by our initial
Magellan System launch in the U.S." 
About the Magellan(TM) Robotic System
 Hansen Medical's Magellan
Robotic System is based upon the flexible robotic technology
incorporated in the Sensei-X(R) Robotic Catheter System currently
sold in the U.S. and Europe, which has been used in more than 9,000
patients, but includes a number of key enhancements. In particular,
the Magellan Robotic System: 

--  Provides solid catheter stability for placement of therapeutic
--  Is designed to enable predictable procedure times and increased case
--  Allows for independent, individual robotic control of the distal tips
    of both the outer sheath and the inner leader catheter, as well as
    robotic manipulation of standard guidewires.
--  Is designed to allow for sufficient extension inside the body to
    access hard to reach peripheral anatomy.
--  Preserves the open architecture featured in the Sensei System to allow
    for the subsequent use of many 6F therapeutic devices on the market
--  Is designed to potentially reduce physician radiation exposure and
    fatigue by employing a remote physician workstation.

About Hansen Medical, Inc.  
Hansen Medical, Inc., based in Mountain View, California, is the
global leader in intravascular robotics, developing products and
technology designed to enable the accurate positioning, manipulation
and control of catheters and catheter-based technologies. The
Company's Magellan(TM) Robotic System, NorthStar(TM) Robotic Catheter
and related accessories, which are intended to facilitate navigation
to anatomical targets in the peripheral vasculature and subsequently
provide a conduit for manual placement of therapeutic devices, have
undergone both CE marking and 510(k) clearance and are commercially
available in the European Union and the U.S. In the European Union,
the Company's Sensei(R) X Robotic Catheter System and Artisan Control
Catheter are cleared for use during electrophysiology (EP)
procedures, such as guiding catheters in the treatment of atrial
fibrillation (AF), and the Lynx(R) Robotic Ablation Catheter is
cleared for the treatment of AF. This robotic catheter system is
compatible with fluoroscopy, ultrasound, 3D surface map and patient
electrocardiogram data. In the U.S. the Company's Sensei X Robotic
Catheter System and Artisan Control Catheter were cleared by the U.S.
Food and Drug Administration for manipulation and control of certain
mapping catheters in EP procedures. In the United States, the Sensei
System is not approved for use in guiding ablation procedures; this
use remains experimental. The U.S. product labeling therefore
provides that the safety and effectiveness of the Sensei X System and
Artisan Control Catheter for use with cardiac ablation catheters in
the treatment of cardiac arrhythmias, including AF, have not been
established. Additional information can be found at
Forward-Looking Statements 
This press release contains forward-looking statements regarding,
among other things, statements relating to goals, plans, objectives,
milestones and future events. All statements, other than statements
of historical fact, are statements that could be deemed
forward-looking statements, including statements containing the words
"plan," "expects," "potential," "believes," "goal," "estimate,"
"anticipates," and similar words. These statements are based on the
current estimates and assumptions of our management as of the date of
this press release and are subject to risks, uncertainties, changes
in circumstances and other factors that may cause actual results to
differ materially from the information expressed or implied by
forward-looking statements made in this press release. Examples of
such statements include statements about the potential benefits of
the Magellan(TM) Robotic System for patients, physicians and
hospitals and our ability to successfully market our new products and
technologies. Important factors that could cause actual results to
differ materially from those indicated by such forward-looking
statements include, among others: the rate of adoption of our systems
and the rate of use of our catheters; the uncertain timelines for the
sales cycle for newly introduced products; the commercial viability
of our products in vascular markets; potential safety and regulatory
issues that could slow or suspend our sales; the effect of credit,
financial and economic conditions on capital spending by our
potential customers; the scope and validity of intellectual property
rights applicable to our products; competition from other companies;
our ability to recruit and retain key personnel; our ability to
maintain our remedial actions over previously reported material
weaknesses in internal controls over financial reporting; our ability
to manage expenses and cash flow, and obtain additional financing;
and other risks more fully described in the "Risk Factors" section of
our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012
filed with the SEC on August 9, 2012 and the risks discussed in our
other reports filed with the SEC. Given these uncertainties, you
should not place undue reliance on the forward-looking statements in
this press release. We undertake no obligation to revise or update
information herein to reflect events or circumstances in the future,
even if new information becomes available.  
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan and
NorthStar are trademarks of Hansen Medical, Inc. in the United States
and other countries. 
Investor Contact
Peter J. Mariani
Chief Financial Officer
Hansen Medical, Inc. 
FTI Consulting, Inc.
Brian Ritchie
John Capodanno
Press spacebar to pause and continue. Press esc to stop.